# Leadership, Planning and Evaluation

> **NIH NIH P30** · STANFORD UNIVERSITY · 2022 · $616,942

## Abstract

SUMMARY
The significant accomplishments of the Stanford Cancer Institute (SCI) in this funding period—described
throughout this renewal application—are evidence of the effectiveness and productivity of a reconfigured and
highly engaged senior leadership, an enhanced leadership structure, and impactful planning and evaluation
processes. Following his 2018 appointment, the SCI Director, Steven Artandi, MD, PhD, adapted leadership
roles and structure to maximize the impact and contributions of the SCI in a highly matrixed organization. Artandi
has transformed the leadership structure by recruiting and appointing new leaders to key Associate Director
positions and broadened input from across the organization to gain rapid consensus on important strategic goals
and the development of new scientific initiatives. Artandi led the first integrated SCI Strategic Plan
encompassing the tripartite—research, education, and clinical missions. The SCI Strategic Plan identified 5
priority areas: Community Engagement, Population Sciences, Training and Education, Clinical Research, and
Translation Science. Implementation of the SCI Strategic Plan is achieved by the robust leadership structure
comprised of the Director’s Leadership Cabinet, the SCI Executive Committee, which includes the Internal
Advisory Board, the Research Program Leaders Committee, the leaders of the Clinical Research Groups, and
committees for SCI Pilot Awards, Shared Resources, Cancer Research Training and Education, and Community
Outreach and Engagement. External guidance is provided by the External Advisory Board (EAB) and the
Community Advisory Board (CAB). The transformative changes to Leadership, Planning and Evaluation (LP&E)
have enabled numerous impactful accomplishments during this funding period, including: (1) recruitment or
appointment of nine new Associate Directors, (2) appointment of a Deputy Director who is an expert in clinical
research, (3) initiation of a new effort in cancer drug discovery, (4) strengthening of Population Sciences and
forming a Department of Epidemiology and Population Health, (5) development of new SCI Shared Resources,
(6) launching a new CAR-T effort, (7) revising and strengthening the Research Programs, (8) inaugurating an
SCI Office of Cancer Health Equity and Community Engagement, (9) forming the CAB, (10) funding the Seed
Grant Program, in collaboration with the CAB, and Community Ambassador Program, and (11) updating the
membership of the EAB. These accomplishments have enabled the SCI to catalyze its growth in salient metrics,
including $91.3M total peer-reviewed funding, $41.9M NCI funding, and 31% collaborative publications during
this funding period and facilitated an increase in accrual to treatment trials by 17% and to investigator-initiated
trials by more than 50% over the past two years. 69 new faculty recruits became SCI members. During the
current funding period, the LP&E capacity of the SCI has enabled remarkable progress in all aspects of...

## Key facts

- **NIH application ID:** 10411087
- **Project number:** 2P30CA124435-14
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** STEVEN E ARTANDI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $616,942
- **Award type:** 2
- **Project period:** 2007-06-04 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10411087

## Citation

> US National Institutes of Health, RePORTER application 10411087, Leadership, Planning and Evaluation (2P30CA124435-14). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10411087. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*